Thrombolex
Overview
Thrombolex, Inc., a privately held medical device company, specializes in the design, production, and distribution of innovative endovascular catheters for treating arterial and venous thromboembolic (A+VTE) conditions. Founded in 2016, the company is based in New Britain, Pennsylvania. Thrombolex has raised a total of $26.8 million in funding. The company's BASHIR™ Endovascular Catheters are a core product line, integrating unique pharmaco-mechanical technologies to provide effective medical interventions.
Recent Developments
- February 2025: Thrombolex announced that the Bashir Endovascular Catheter developed in partnership with Dr. Riyaz Bashir has saved over 2,000 lives. This development was celebrated by local government officials, highlighting the state investment in the life-saving device. Thrombolex plans to expand the device's reach outside the United States.
- January 2025: The company began enrolling patients in the RAPID-PE postmarket study, assessing the Bashir catheter's efficacy in treating acute pulmonary embolism without the need for post-procedural thrombolytic infusion.
- October 2024: Thrombolex announced the results of the RESCUE II Trial, demonstrating the Bashir catheter's efficacy in pharmacomechanical lysis treatment for pulmonary embolism.
- July 2024: Thrombolex, in partnership with Aidoc, announced advancements in pulmonary embolism treatment using AI technology to accelerate clinical trials.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2016 |
| Headquarters | New Britain, Pennsylvania, USA |
| Founders | Riyaz Bashir, Marvin Woodall, Michael Cerminaro |
| Revenue | $2 million (2025) |
| Profits | N/A |
| Key Investors | National Heart, Lung, and Blood Institute; Delaware Crossing Investor Group |
| Industry | Medical Devices |
| Number of Employees | 21 |
Early History
Thrombolex was founded in 2016 by a team of medical professionals and entrepreneurs, including Dr. Riyaz Bashir, who played a pivotal role in the development of the Bashir Endovascular Catheters. The company quickly positioned itself within the medical device industry by focusing on novel therapeutic solutions for thromboembolic conditions. The initial venture capital was used to develop and test their key devices, which led to several FDA clearances.
Company Profile and Achievements
Thrombolex's strategic focus centers on innovative catheters for treating thromboembolic conditions. The company leverages the BASHIR™ Endovascular Catheter technology, allowing precise and efficient delivery of thrombolytics. Key achievements include:
- FDA Clearances: The BASHIR series of catheters received multiple FDA clearances, validating their safety and efficacy for clinical use.
- Clinical Trials: The company conducted significant trials like RESCUE and RAPID-PE, demonstrating the effectiveness of their devices.
- Strategic Partnerships: Collaborations with local government and partners like Aidoc have accelerated product development and market penetration.
- Awarded Funding: More than $26.8 million has been raised to date, with substantial contributions from notable health institutions.
Current Operations and Market Position
Thrombolex operates at the intersection of medical technology and treatment innovation for thromboembolic diseases. It maintains a competitive edge through its advanced catheter technologies, which offer procedural efficiency and improved patient outcomes. Thrombolex's devices are employed in numerous hospitals across the U.S., with a strong focus on expanding globally.
Conclusion
Thrombolex has carved a niche in the medical device industry with its compelling innovations in thrombus treatment. As the company progresses, its dedication to improving clinical outcomes through advanced endovascular solutions is expected to bolster its market position. Future expansions, enhanced by ongoing research and strategic partnerships, aim to broaden its impact on global healthcare systems, solidifying its role as a leader in the field of thromboembolic treatment devices.